PIK3CA was identified as one of the most commonly mutated “driver genes” in endometrial tumors and, accordingly, multiple PI3KCA, AKT and mTOR targeted inhibitors are currently in Phase I-III clinical trials against solid tumors including endometrial cancer. This evidence concerns the gene MTOR and endometrial cancer.